September 15, 2020
REGENXBIO Inc. et al v. Sarepta Therapeutics, Inc., et al.
Case Number:
1:20-cv-01226
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
January 05, 2024
Sarepta Avoids IP Claims As Judge Finds UPenn Patent Invalid
A Delaware judge found a gene therapy patent at the center of an infringement suit against Sarepta, brought by the University of Pennsylvania, was ineligible for patent protection because the claims cover a combination of two recombinant DNA sequences that are already naturally occurring.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login